GlassScriptPhysician profile
Richard J Jirovec
NPI 1033168174
$3,860.63
in general payments reported to CMS, 2019-2025
27 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $408 · 2021: $977 · 2022: $930 · 2023: $254 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $750 · Food and Beverage: $54.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $750.00 |
| Food and Beverage | $54.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sekisui Diagnostics LLC | $1,190.00 | 2022-2025 | |
| Novo Nordisk INC | $488.56 | 2019-2023 | Ozempic, Rybelsus |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $339.16 | 2019-2022 | |
| Becton, Dickinson and Company | $183.33 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.22 | 2021-2022 | |
| Abbvie INC. | $173.57 | 2020-2023 | |
| Lilly USA, LLC | $157.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $102.78 | 2020-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Allergan, INC. | $98.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $80.00 | 2021 | |
| Genzyme Corporation | $60.00 | 2020 | |
| Sanofi Pasteur INC. | $42.86 | 2020-2022 | |
| Antares Pharma, INC. | $42.72 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $39.76 | 2019-2022 | |
| Amgen INC. | $38.64 | 2019-2022 | |
| Pfizer INC. | $28.67 | 2021-2022 | |
| Abbott Laboratories | $21.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.19 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.90 | 2022 | |
| Upsher-Smith Laboratories LLC | $19.70 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.71 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.47 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.72 | 2021 | |
| Axsome Therapeutics, INC. | $14.43 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Jirovec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.